Astex Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Astex Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Astex Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Astex Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Astex Pharmaceuticals, Inc.

The report provides overview of Astex Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Astex Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Astex Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Astex Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Astex Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Astex Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Astex Pharmaceuticals, Inc. Snapshot 6

Astex Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Astex Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Astex Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Astex Pharmaceuticals, Inc. - Pipeline Products Glance 15

Astex Pharmaceuticals, Inc. - Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Astex Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Astex Pharmaceuticals, Inc. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Astex Pharmaceuticals, Inc. - Drug Profiles 20

guadecitabine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

AT-7519 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

AT-9283 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

onalespib 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

(decitabine + E-7727) 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ASTX-660 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

AT-13148 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AT-26893 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Activate PKM2 for Lung Adenocarcinoma 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules to Inhibit MetAP2 for Colon Cancer 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecule to Inhibit PAK1 for Oncology 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules for Undisclosed Indication 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecules to Antagonize DDR1 and DDR2 Receptors for Oncology 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules to Inhibit TNIK for Oncology 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Astex Pharmaceuticals, Inc. - Pipeline Analysis 44

Astex Pharmaceuticals, Inc. - Pipeline Products by Target 44

Astex Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 46

Astex Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 47

Astex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 48

Astex Pharmaceuticals, Inc. - Recent Pipeline Updates 50

Astex Pharmaceuticals, Inc. - Dormant Projects 59

Astex Pharmaceuticals, Inc. - Discontinued Pipeline Products 60

Discontinued Pipeline Product Profiles 60

amuvatinib 60

onalespib 60

Astex Pharmaceuticals, Inc. - Locations And Subsidiaries 61

Head Office 61

Other Locations & Subsidiaries 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Astex Pharmaceuticals, Inc., Key Information 6

Astex Pharmaceuticals, Inc., Key Facts 6

Astex Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Astex Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Astex Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Astex Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2016 12

Astex Pharmaceuticals, Inc. – Out-Licensed Products in Pipeline, 2016 13

Astex Pharmaceuticals, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Astex Pharmaceuticals, Inc. – Phase III, 2016 15

Astex Pharmaceuticals, Inc. – Phase II, 2016 16

Astex Pharmaceuticals, Inc. – Phase I, 2016 17

Astex Pharmaceuticals, Inc. – Preclinical, 2016 18

Astex Pharmaceuticals, Inc. – Discovery, 2016 19

Astex Pharmaceuticals, Inc. – Pipeline by Target, 2016 44

Astex Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 46

Astex Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 47

Astex Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 48

Astex Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 50

Astex Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 59

Astex Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 60

Astex Pharmaceuticals, Inc., Other Locations 61

Astex Pharmaceuticals, Inc., Subsidiaries 61

List of Figures

List of Figures

Astex Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

Astex Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Astex Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Astex Pharmaceuticals, Inc. – Out-Licensed Products in Pipeline, 2016 13

Astex Pharmaceuticals, Inc. – Pipeline by Top 10 Target, 2016 44

Astex Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 46

Astex Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 47

Astex Pharmaceuticals, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 48

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports